title: Inhibition of endocytic processes by photodynamic therapy.
abstract: OBJECTIVE
  Recent studies have demonstrated an effect of photodamage on the endocytic pathway involved in recycling of membrane components. Using a series of agents with known sub-cellular targets, we explored the determinants of photodynamic inhibition of endocytic processes in three cell lines: A murine leukemia, a murine hepatoma, and a non-malignant epithelial cell line of human origin.
  
  
  METHODS
  The PI-3 kinase antagonist wortmannin blocks endosomal processing pathway dependent on this enzyme, providing an indication of the "flux" of endocytosis. Microscopic observations were used to assess the effect of photodamage on this pathway. Photosensitizing agents specific for mitochondrial, endoplasmic reticulum (ER), lysosomal, and endosomal photodamage were employed.
  
  
  RESULTS
  Sub-lethal photodamage directed against endosomes or lysosomes interrupted early steps in this endocytic process in the hepatoma cell line. A mechanism for these effects is proposed. Mitochondrial photodamage could interrupt endocytosis, but at levels that also induced apoptosis. ER photodamage did not affect endocytosis even at lethal levels. Somewhat similar results were obtained with other cell lines, but there were sufficient differences to indicate that the cell phenotype is, in part, a determinant of the endocytic response to PDT.
  
  
  CONCLUSIONS
  PDT is therefore seen to have an effect on endocytic processes. Further work will be needed to delineate the role of these endocytic effects in the array of responses to photodynamic therapy.
authors: Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA. dhkessel@med.wayne.edu
authors: David
authors: D
authors: Kessel
mesh_terms: D000730:Androstadienes / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D002460:Cell Line; D045744:Cell Line, Tumor; D004705:Endocytosis / Q000187:drug effects*; D004847:Epithelial Cells / Q000187:drug effects; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use; D007938:Leukemia / Q000188:drug therapy; D008113:Liver Neoplasms / Q000188:drug therapy; D008652:Mesoporphyrins / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D008954:Models, Biological; D015388:Organelles / Q000187:drug effects / Q000502:physiology; D009942:Organometallic Compounds / Q000494:pharmacology / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000494:pharmacology* / Q000627:therapeutic use; D011166:Porphyrins / Q000494:pharmacology / Q000627:therapeutic use; D000077191:Wortmannin
chemical_list: D000730:Androstadienes; D007211:Indoles; D008652:Mesoporphyrins; D009942:Organometallic Compounds; D010726:Phosphodiesterase Inhibitors; D017319:Photosensitizing Agents; D011166:Porphyrins; C504224:benzoporphyrin D; C064331:aluminum phthalocyanine disulfonate; C072269:temoporfin; C053434:Talaporfin; D000077191:Wortmannin